PLoS ONE (Jan 2014)

Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.

  • Juliana Giacomazzi,
  • Marcia S Graudenz,
  • Cynthia A B T Osorio,
  • Patricia Koehler-Santos,
  • Edenir I Palmero,
  • Marcelo Zagonel-Oliveira,
  • Rodrigo A D Michelli,
  • Cristovam Scapulatempo Neto,
  • Gabriela C Fernandes,
  • Maria Isabel W S Achatz,
  • Ghyslaine Martel-Planche,
  • Fernando A Soares,
  • Fernando A Soares,
  • Maira Caleffi,
  • José Roberto Goldim,
  • Pierre Hainaut,
  • Suzi A Camey,
  • Patricia Ashton-Prolla

DOI
https://doi.org/10.1371/journal.pone.0099893
Journal volume & issue
Vol. 9, no. 6
p. e99893

Abstract

Read online

Germline TP53 mutations predispose individuals to multiple cancers and are associated with Li-Fraumeni/Li-Fraumeni-Like Syndromes (LFS/LFL). The founder mutation TP53 p.R337H is detected in 0.3% of the general population in southern Brazil. This mutation is associated with an increased risk of childhood adrenal cortical carcinoma (ACC) but is also common in Brazilian LFS/LFL families. Breast Cancer (BC) is one of the most common cancers diagnosed in TP53 mutation carriers. We have assessed the prevalence of p.R337H in two groups: (1) 59 BC affected women with a familial history (FH) suggestive of hereditary cancer syndrome but no LFS/LFL features; (2) 815 BC affected women unselected for cancer FH, diagnosed with BC at or before age 45 or at age 55 or older. Among group 1 and group 2 patients, 2/59 (3.4%, CI95%: 0.4%-11.7%) and 70/815 (8.6%, CI95%: 6.8%-10.7%), respectively, were p.R337H carriers in the germline. The prevalence of p.R337H was higher in women diagnosed with BC at or before age 45 (12.1%, CI95%: 9.1%-15.8%) than at age 55 or older (5.1%, CI95%: 3.2%-7.7%), p<0.001). The Brazilian founder p.R337H haplotype was detected in all carriers analysed. These results suggest that inheritance of p.R337H may significantly contribute to the high incidence of BC in Brazil, in addition to its recently demonstrated impact on the risk of childhood ACC.